Skip to main content
. 2015 Jul 17;6(28):25988–26001. doi: 10.18632/oncotarget.4620

Figure 2. Proteomic analysis of altered proteins in bortezomib-treated human Burkitt's lymphoma cells.

Figure 2

Daudi cells were treated with 10 nM bortezomib (Bz) for 12 h, total cellular proteins were subjected to two-dimensional electrophoresis, and altered proteins were identified by MALDI-Q-TOF. A. Upregulated and B. downregulated proteins. Ctrl, control.